AI in Bio Sees Significant Advancements and Investment

@nathanbenaich· June 18, 2026 View original

▶ The 60-second brief

Summary

Recent weeks have seen major developments in AI for biology, including a multi-billion dollar deal for AI-designed gene editors, new base-editing data, and scaling results for protein models. A podcast discusses these trends, focusing on the shift from discovery to design in biology and the "GPT-1.5 era" of the field.

The field of artificial intelligence in biology has experienced a period of rapid progress and substantial investment. This includes a significant $2.25 billion collaboration between Profluentbio and Eli Lilly and Company focused on AI-powered gene editing technologies. Further advancements involve new data in base-editing from Verve and improved scaling results for protein models from CZ Biohub, alongside notable achievements by Isomorphic Labs. These developments highlight a pivotal moment in how AI is being applied to biological research and development. A recent podcast delves into these topics, exploring the transition from traditional biological discovery to AI-driven design. The discussion also covers different approaches to protein modeling, such as sequence-first versus structure-first methods, and characterizes the current state of AI in biology as its "GPT-1.5 era," suggesting a phase of significant foundational development.

Why it matters

Professionals should care because these developments signal a major acceleration in biotech innovation, driven by AI, which could lead to breakthroughs in medicine, drug discovery, and genetic engineering. Understanding these trends is crucial for strategic planning and investment in related sectors.

How to implement this in your domain

  1. 1Monitor emerging AI-bio partnerships and investment trends to identify future growth areas.
  2. 2Evaluate potential applications of AI-designed gene editors or protein models within your organization's research pipeline.
  3. 3Investigate "sequence-first" vs. "structure-first" AI approaches for biological problems relevant to your work.
  4. 4Attend webinars or read reports on the "GPT-1.5 era" of biology to grasp foundational shifts.

Who benefits

BiotechPharmaceuticalsHealthcareLife SciencesVenture Capital

Key takeaways

  • AI is driving significant investment and innovation in the biotechnology sector.
  • Major deals are emerging for AI-designed gene editing technologies.
  • New research is advancing protein modeling and base-editing capabilities.
  • The field is transitioning from biological discovery to AI-driven design.

Original post by @nathanbenaich

"it's been a huge few weeks for ai in bio: a $2.25b @profluentbio x @elilillyandco deal on ai-designed gene editors, verve's base-editing data, new scaling results on protein models from @czbiohub, @isomorphiclabs' haul. @thisismadani and i recorded a pod diving into all of it we…"

View on X

Originally posted by @nathanbenaich on X · view source

Want to go deeper?

Turn these trends into skills with Learnijoy's hands-on AI & tech courses.

Explore courses